Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is in the highlights and many would want to know whether now might be a good time for it to present much upside. Now trading with a market value of 407.07M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ACHN, the company currently has 52.09 million of cash on the books, which is offset by 201,000 in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 360.44 million in total assets, balanced by 14.71 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Achillion Pharmaceuticals, Inc. (ACHN) saw -16.79 million in free cash flow last quarter, representing a quarterly net change in cash of 16.7 million. Perhaps most importantly where cash movements are concerned, the company saw about -16.57 million in net operating cash flow.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the ACHN saw sales decline by 0.00.
But what about the bottom line? After all, that’s what really matters in the end. Achillion Pharmaceuticals, Inc. (ACHN) is intriguing when broken down to its core data. The cost of selling goods last quarter was 277,000, yielding a gross basic income of -277,000 . For shareholders, given the total diluted outstanding shares of 137.38 million, this means overall earnings per share of -0.14. Note, this compares with a consensus analyst forecast of -0.15 in earnings per share for its next fiscal quarterly report.
Is Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Valuation Attractive
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.67 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Achillion Pharmaceuticals, Inc..